| Identification | Back Directory | [Name]
BHPI | [CAS]
56632-39-4 | [Synonyms]
BHPI
CS-2134
1,3-Dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl-2H-indol-2-one
2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- | [Molecular Formula]
C21H17NO3 | [MOL File]
56632-39-4.mol | [Molecular Weight]
331.36 |
| Chemical Properties | Back Directory | [Melting point ]
272-274 °C | [Boiling point ]
557.7±50.0 °C(Predicted) | [density ]
1.320±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMF: 5 mg/ml; DMSO: 11 mg/ml; Ethanol: 14 mg/ml; Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml | [form ]
A crystalline solid | [pka]
9.43±0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
BHPI is an antagonist of estrogen receptor α (ERα) that blocks 17β-estradiol-induced proliferation of drug-resistant breast, endometrial, and ovarian cancer cell lines at concentrations ranging from 10 to 1,000 nM. It is effective in vivo, driving tumor regression in mice bearing MCF-7 xenografts at a dose of 15 mg/kg daily. BHPI specifically inhibits ERα-dependent gene expression and protein synthesis by activating the unfolded protein response in cells. | [Uses]
BHPI is an antagonist of estrogen receptor α (ERα) that blocks 17β-estradiol-induced proliferation of drug-resistant breast, endometrial and ovarian cancer cell lines. | [in vivo]
BHPI (10-15 mg/kg; i.p.; daily, 10 days or every other day, until the end of the experiment) inhibits tumor growth and results in rapid regression of 48/52 tumors in a mouse xenograft model using MCF-7 tumors[1].
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|